MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$216,925K
Free Cash flow
-$40,615K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts payable and accrued lia...
Stock-based compensation expense
Proceeds from exercise of stock ...
Others
Negative Cash Flow Breakdown
Purchases of available-for-sale ...
Prepaid expenses, other current ...
Proceeds from underwritten publi...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Net loss
-83,233
-49,198
Stock-based compensation expense
3,171
4,696
Non-cash operating lease expense
326
619
Loss on assignment of finance lease
0
158
Depreciation and amortization
28
63
Amortization of finance lease right-of-use asset
0
13
Non-cash interest expense
0
7
Gain on disposal of property and equipment
0
48
Accretion of discounts, net of amortization of premiums, on available-for-sale investments
166
-
Reversal due to settlement of indirect tax liabilities
0
-9,445
Loss on disposal of discontinued operations
0
0
Amortization of costs to obtain a contract with a customer
0
0
Accounts receivable
2
165
Inventory
0
0
Prepaid expenses, other current assets, and other assets
24,971
206
Accounts payable and accrued liabilities
63,564
-4,819
Accrued indirect tax liabilities
138
-1,665
Accrued compensation and benefits
879
-2,252
Contract liabilities
0
0
Operating lease liabilities
-349
-669
Net cash used in operating activities
-40,615
-62,911
Purchases of available-for-sale investments
176,470
-
Proceeds from sales of property and equipment
0
185
Purchases of property and equipment
0
0
Net cash used in investing activities
-176,470
185
Proceeds from underwritten public offering, net of issuance costs
-1,215
378,125
Proceeds from at-the-market offering of common stock, net of issuance costs
-5
4,126
Proceeds from exercise of stock options
1,517
1,124
Proceeds from private placement, net of issuance costs
0
0
Deferred financing costs
-
137
Payment of finance lease liabilities
0
50
Payment for shares withheld to fund payroll taxes
0
0
Net cash provided by financing activities
160
383,462
Net increase in cash, cash equivalents and restricted cash
-216,925
320,736
Cash and cash equivalents at beginning of period
196,177
-
Cash and cash equivalents at end of period
299,988
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
stock options
$1,517K
Net cash provided by
financing activities
$160K
Canceled cashflow
$1,357K
Net increase in
cash, cash...
-$216,925K
Canceled cashflow
$160K
Accounts payable and
accrued liabilities
$63,564K
Stock-based compensation
expense
$3,171K
Accrued compensation
and benefits
$879K
Non-cash operating lease
expense
$326K
Accrued indirect tax
liabilities
$138K
Depreciation and
amortization
$28K
Proceeds from
underwritten public...
-$1,215K
something is missing
-$137K
Proceeds from
at-the-market offering of...
-$5K
Net cash used in
investing activities
-$176,470K
Net cash used in
operating activities
-$40,615K
Canceled cashflow
$68,106K
Purchases of
available-for-sale investments
$176,470K
Net loss
-$83,233K
Prepaid expenses, other
current assets, and...
$24,971K
Operating lease
liabilities
-$349K
Accretion of discounts,
net of amortization...
$166K
Accounts receivable
$2K
Buy us a coffee
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. (CDTX)